The treatment of uveitis is undergoing significant change as a result of the development of new therapeutic approaches, of which the biologic agents form a major part. These targeted therapies have shown great promise for the treatment of refractory disease and some have now undergone systematic evaluation through prospective clinical trials, unlike many of their predecessor drugs.
EUROPEAN OPHTHALMIC REVIEW approaches include reducing antigen presentation by blocking lymph node efflux via the sphingosine-1-phosphate receptor (fingolimod), targeting B cells (rituximab), and reducing inflammatory cell migration via α4-integrin (natalizumab).
It is an exciting time in uveitis research -there are more therapeutic options than ever before, yet there are also more questions about how and when to use them; the future should hold interesting developments for researchers, clinicians and patients. ■
